Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

This study has been completed.
Sponsor:
Collaborator:
Schering-Plough
Information provided by (Responsible Party):
Centocor, Inc.
ClinicalTrials.gov Identifier:
NCT01248780
First received: November 24, 2010
Last updated: August 12, 2013
Last verified: August 2013

November 24, 2010
August 12, 2013
September 2010
October 2011   (final data collection date for primary outcome measure)
American College of Rheumatology (ACR) 20 Response, Using CRP (C-reactive Protein), at Week 14 [ Time Frame: Week 14 ] [ Designated as safety issue: No ]
ACR 20 response is defined as >= 20% improvement in rheumatoid arthritis (RA) symptoms and disease activity.
American College of Rheumatology (ACR) 20 response [ Time Frame: Week 14 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01248780 on ClinicalTrials.gov Archive Site
  • Disease Activity Index Score (DAS 28) Response, Using CRP (C-reactive Protein) [ Time Frame: Week 14 ] [ Designated as safety issue: No ]
    DAS28 using CRP is a measure of tender and swollen joints (28 joints each) and the patient's assessments of disease activity. A score of higher than 5.1 indicates high disease activity, and a score below 3.2 indicates low disease activity. A DAS28 (using CRP) responder is defined as a participant with a DAS28 response of "Good" or "Moderate" at Week 14. A "Good" response is defined as a patient with a DAS28 score of <= 3.2 at Week 14 with improvement from Baseline in DAS28 score of > 1.2. A "Moderate" response was defined as a patient with DAS28 score of >3.2-5.1 at Week 14 with improvement from baseline in DAS28 score of >0.6 to >1.2 The table below shows the number of participants in each treatment group who were DAS28 responders at Week 14.
  • American College of Rheumatology 20 Response, Using CRP, at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    ACR 20 response is defined as >= 20% improvement in rheumatoid arthritis (RA) symptoms and disease activity.
  • HAQ (Disability Index of the Health Assessment Questionnaire) Score Change From Baseline [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    The HAQ assesses the degree of difficulty a person has in accomplishing tasks in 8 categories (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). The full range of the HAQ scale is 0-24 with 0 being the best possible outcome. The HAQ score is calculated as the sum of the category scores divided by the number of categories scored, giving a possible range of scores from 0 to 3 with 0 being the best possible outcome (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, or 3=unable to do). The mean change from baseline at Week 24 in HAQ score is provided below for each treatment group. A negative change from baseline is indicative of a lesser degree of difficulty in accomplishing tasks assessed in the HAQ.
  • Disease Activity Index Score (DAS 28) Response [ Time Frame: Week 14 ] [ Designated as safety issue: No ]
  • American College of Rheumatology 20 response [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • HAQ (Disability Index of the Health Assessment Questionnaire) score change from baseline [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy

The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese patients with rheumatoid arthritis.

Golimumab is a type of tumor necrosis factor (TNF)-inhibitor. TNF is a naturally occurring substance in the body, and this substance may cause long-term inflammation. Golimumab may help fight disease by blocking the activity of TNF in the body and reducing inflammation and pain. Each patient who is allowed to join the study will be put into a group randomly, like flipping a coin. Patients may get either golimumab or placebo (which looks like the drug being studied but has no active ingredients, for example a sugar pill). The chance that the patient will get golimumab is 1 to 1, a 50% chance to receive golimumab and a 50% chance to receive placebo. If the patient does not have an improvement in their joints at the Week 16 visit compared to when they entered the study, and are in Group 1 (placebo group), the patient will receive golimumab 50 mg every 4 weeks starting at Week 16. If the patient is in Group 2 (golimumab 50 mg), the patient will continue to receive golimumab every 4 weeks starting at Week 16. If the patient is in Group 1 and is still receiving placebo injections, because there was improvement in their joints at Week 16, the patient will receive golimumab 50 mg every 4 weeks starting from Week 24. If the patient is in Group 2 (golimumab 50 mg) or is already receiving golimumab injections at week 24, the patient will continue to receive golimumab every 4 weeks. Safety will be monitored throughout the study, including drawing blood and looking at laboratory tests, vital signs (e.g., blood pressure), and the frequency and type of adverse events (side effects). The patient will be in the study approximately 56 weeks. Patients will receive placebo or active compound (golimumab 50 mg subcutaneous injections) every four weeks from randomization (Week 0) until Week 48.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Rheumatoid Arthritis
  • Drug: Golimumab
    50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
  • Drug: Placebo
    Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
  • Drug: Methotrexate (MTX)
    A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
  • Experimental: Golimumab + methotrexate (MTX)
    Participants will receive golimumab 50 mg as subcutaneous (SC) (under the skin) injections administered every 4 weeks for up to 48 weeks. In addition, participants will receive a stable dose of MTX.
    Interventions:
    • Drug: Golimumab
    • Drug: Methotrexate (MTX)
  • Experimental: Placebo + methotrexate (MTX)
    Participants will be administered Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48. In addition, participants will receive a stable dose of MTX.
    Interventions:
    • Drug: Placebo
    • Drug: Methotrexate (MTX)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
264
July 2012
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

- Diagnosis of rheumatoid arthritis for at least 6 months

  • Be on a stable dose of methotrexate for 4 weeks
  • Have at least 4 swollen and 4 tender joints

Exclusion Criteria:

  • Prior exposure to biologic anti-TNFalpha agents
  • Inflammatory diseases other than rheumatoid arthritis
  • Treatment with Disease Modifying Anti-rheumatic drug (DMARDs)/systemic immunosuppressives other than methotrexate during the 4 weeks prior to the first administration of study agent
  • History of, or ongoing, chronic or recurrent infectious disease
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
China
 
NCT01248780
CR015913, C0524T28
No
Centocor, Inc.
Centocor, Inc.
Schering-Plough
Study Director: Centocor, Inc. Clinical Trial Centocor, Inc.
Centocor, Inc.
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP